COVID-19 vaccines protect against severe disease. But people with underlying health conditions remain at risk of infection and associated complications. This study will evaluate immune responses after infection or vaccination in healthy and vulnerable people. The findings will inform future clinical care for COVID-19 and targeted approaches to improve vaccine responses in vulnerable patient groups.
We're evaluating antibody and cellular immune responses after infection or vaccination in healthy and vulnerable people to evaluate their protection against future variants.
We'll comprehensively profile the immune responses to the COVID-19 virus (SARS-CoV-2) using clinical samples collected from 11 vulnerable and immunocompromised cohorts (adults and paediatrics) and healthy individuals who have been vaccinated. Serological antibody responses and cellular responses T-cells and B-cell will be measured.
Generating knowledge and evidence to improve vaccine schedules, future booster strategies and improved access to clinical care for vulnerable populations. In addition, our findings will inform future clinical trials to enhance vaccine responses in immunocompromised people.
2022–2026.
Journal of Infection
P. Mark Hogarth
Clinical & Translational Immunology
Shir Sun, Irene Boo, Heidi E. Drummer, Gabriela Khoury, Irene Boo, Shir Sun, Heidi E. Drummer, Gabriela Khoury
Journal of Clinical Immunology
Irene Boo, P. Mark Hogarth, Heidi E. Drummer
Medical Research Future Fund (MRFF): 2021 COVID-19 Treatment Access and Public Health Activities.